Hematological ratios, immune-related adverse events and mortality in patients treated with immune checkpoint inhibitors
In this study, pretreatment inflammation-based hematological ratios were not associated with future immune-related adverse events in patients treated with checkpoint inhibitors. However, elevated hematological ratios were associated with an increased mortality risk.
Authors
- Karin H. Herbschleb
- Saskia Haitjema (ORCID: https://orcid.org/0000-0001-5465-4868)
- Cornelia A. R. Hulsbergen-Veelken (ORCID: https://orcid.org/0000-0003-4375-2221)
- Karin A. H. Kaasjager (ORCID: https://orcid.org/0000-0001-6958-8285)
- Marianne Christina Verhaar (ORCID: https://orcid.org/0000-0002-3276-6428)
- Gürbey Ocak (ORCID: https://orcid.org/0000-0003-4288-7685)
- Meriem Khairoun (ORCID: https://orcid.org/0000-0003-4833-9639)
- Sophie Lekkerkerker
Institutions
- University Medical Center Utrecht (NL)
- St. Antonius Ziekenhuis (NL)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1371/journal.pone.0336491
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00